News & Insights
Latest News
- May 20, 2026 Acuitas Therapeutics Highlights In Vivo CAR T Cell Engineering and Ionizable Lipid Quality Attributes at the 2026 ASGCT Annual Meeting
- April 27, 2026 Acuitas Therapeutics Announces Four Scientific Presentations at the 2026 ASGCT Annual Meeting
- April 13, 2026 Acuitas Therapeutics To Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Latest Presentations
-
May 28, 2026 LNP Technology for Infectious Disease and Cancer mRNA Vaccines
-
May 25, 2026 Optimization of ALC-315® Yields Superior Ionizable Lipids for LNP Mediated Nucleic Acid Delivery
-
May 15, 2026 Ionizable lipid impurities drive RNA-lipid adduct formation in LNPs, impacting in vivo expression (Presentation)
Page: /
Latest Publications
- July 6, 2026 Marchitto et al. (2026) “Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies” Nature.
- May 26, 2026 Cohen et al. (2026) “mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures” Cell Reports.
- May 13, 2026 Tálas et al. (2026) “RNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I” Science Translational Medicine.